Recent Advancements for the Management of Pancreatic Cancer: Current Insights

Abstract

One of the most fatal forms of cancer includes cancer of the pancreas And the most rapid malignancy is observed in PDAC (pancreatic ductal adenocarcinoma). The high lethality rate is generally due to very late diagnosis and resistance to traditional chemotherapeutic agents. Desmoplastic stromal barrier results in resistance to immunotherapy. Other reasons for the high lethality rate include the absence of effective treatment and standard screening tests. Hence, there is a need for effective novel carrier systems. “A formulation, method, or device that allows the desired therapeutic substance to reach its site of action in such a manner that nontarget cells experience minimum effect is referred to as a drug delivery system”. The delivery system is responsible for introducing the active component into the body. They are also liable for boosting the efficacy and desirable targeted action on the tumorous tissues. Several studies, researches, and developments have yielded various advanced drug delivery systems, which include liposomes, nanoparticles, carbon nanotubules, renovoCath, etc. These systems control rate and location of the release. They are designed while taking into consideration characteristic properties of the tumor and tumor stroma. These delivery systems overcome the barriers in drug deliverance in pancreatic cancer. Alongside providing palliative benefits, these delivery systems also aim to correct the underlying reason for the defect. The following review article aims and focuses to bring out a brief idea about systems, methods, and technologies for futuristic drug deliverance in pancreatic cancer therapy.